Smalley KS - Search Results

1

Selective evolutionary pressure from the tissue microenvironment drives tumor progression.

Smalley KS, Brafford PA, Herlyn M. Smalley KS, et al. Semin Cancer Biol. 2005 Dec;15(6):451-9. doi: 10.1016/j.semcancer.2005.06.002. Semin Cancer Biol. 2005. PMID: 16043361 Review.

2

Targeting the stromal fibroblasts: a novel approach to melanoma therapy.

Smalley KS, Lioni M, Herlyn M. Smalley KS, et al. Expert Rev Anticancer Ther. 2005 Dec;5(6):1069-78. doi: 10.1586/14737140.5.6.1069. Expert Rev Anticancer Ther. 2005. PMID: 16336098 Review.

3

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.

Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M. Liu ZJ, et al. Among authors: smalley ks. Cancer Res. 2006 Apr 15;66(8):4182-90. doi: 10.1158/0008-5472.CAN-05-3589. Cancer Res. 2006. PMID: 16618740

4

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.

Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Smalley KS, et al. Mol Cancer Ther. 2006 May;5(5):1136-44. doi: 10.1158/1535-7163.MCT-06-0084. Mol Cancer Ther. 2006. PMID: 16731745

5

Life isn't flat: taking cancer biology to the next dimension.

Smalley KS, Lioni M, Herlyn M. Smalley KS, et al. In Vitro Cell Dev Biol Anim. 2006 Sep-Oct;42(8-9):242-7. doi: 10.1290/0604027.1. In Vitro Cell Dev Biol Anim. 2006. PMID: 17163781 Review.

6

Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells.

Lioni M, Brafford P, Andl C, Rustgi A, El-Deiry W, Herlyn M, Smalley KS. Lioni M, et al. Among authors: smalley ks. Am J Pathol. 2007 Feb;170(2):709-21. doi: 10.2353/ajpath.2007.060343. Am J Pathol. 2007. PMID: 17255337 Free PMC article.

7

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.

Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL. Smalley KS, et al. Cancer Res. 2008 Jul 15;68(14):5743-52. doi: 10.1158/0008-5472.CAN-08-0235. Cancer Res. 2008. PMID: 18632627 Free PMC article.

8

Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy.

Smalley KS, Herlyn M. Smalley KS, et al. Int J Cancer. 2009 Mar 15;124(6):1245-50. doi: 10.1002/ijc.24129. Int J Cancer. 2009. PMID: 19089923 Review.

9

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.

Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M. Lee JT, et al. Among authors: smalley ks. Pigment Cell Melanoma Res. 2010 Dec;23(6):820-7. doi: 10.1111/j.1755-148X.2010.00763.x. Pigment Cell Melanoma Res. 2010. PMID: 20973932 Free PMC article.

10

In vitro three-dimensional tumor microenvironment models for anticancer drug discovery.

Smalley KS, Lioni M, Noma K, Haass NK, Herlyn M. Smalley KS, et al. Expert Opin Drug Discov. 2008 Jan;3(1):1-10. doi: 10.1517/17460441.3.1.1. Expert Opin Drug Discov. 2008. PMID: 23480136

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters